| scholarly article | Q13442814 |
| P50 | author | Wafik El-Deiry | Q4118647 |
| Heinz-Josef Lenz | Q89668545 | ||
| P2093 | author name string | Anthony F Shields | |
| Philip A Philip | |||
| Benjamin A Weinberg | |||
| Jimmy J Hwang | |||
| John L Marshall | |||
| Zoran Gatalica | |||
| Joanne Xiu | |||
| Mohamed E Salem | |||
| P2860 | cites work | Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 |
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. | Q27853216 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival | Q28277824 | ||
| Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer | Q28299100 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter | Q30276647 | ||
| Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. | Q30313824 | ||
| Is there a difference in survival between right- versus left-sided colon cancers? | Q34594168 | ||
| Estrogen receptors and their implications in colorectal carcinogenesis | Q35037282 | ||
| Mutational analysis and clinical correlation of metastatic colorectal cancer | Q35082873 | ||
| Primary tumor location as a prognostic factor in metastatic colorectal cancer. | Q36047405 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. | Q36843773 | ||
| PIK3CA mutations in advanced cancers: characteristics and outcomes | Q36926111 | ||
| Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses | Q37059782 | ||
| Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer | Q37103052 | ||
| Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels | Q37130135 | ||
| Gender disparities in metastatic colorectal cancer survival | Q37426816 | ||
| Boundaries, junctions and transitions in the gastrointestinal tract | Q37908466 | ||
| Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials | Q38386724 | ||
| Rectal and colon cancer: Not just a different anatomic site. | Q38543019 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine | Q38732716 | ||
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. | Q40933980 | ||
| Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma | Q42375951 | ||
| Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer | Q42878733 | ||
| Mechanisms of tolerance to DNA damaging therapeutic drugs | Q43829355 | ||
| Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer | Q44949817 | ||
| Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 | ||
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer | Q46742453 | ||
| Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. | Q50213127 | ||
| Frequency of HER-2 positivity in rectal cancer and prognosis. | Q51283402 | ||
| Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. | Q51552580 | ||
| Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. | Q52857816 | ||
| Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. | Q54509870 | ||
| P433 | issue | 49 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 86356-86368 | |
| P577 | publication date | 2017-09-21 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers | |
| P478 | volume | 8 |
| Q92445909 | "Bridging the Gap" Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era |
| Q92713865 | An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients |
| Q54969912 | Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations. |
| Q64114213 | Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study |
| Q99580038 | CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival |
| Q93156388 | Clinicopathologic and Racial/Ethnic Differences of Colorectal Cancer Among Adolescents and Young Adults |
| Q64229063 | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
| Q90480476 | Comparative mutational analysis of distal colon cancer with rectal cancer |
| Q90289571 | Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma |
| Q90392916 | Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab |
| Q90190600 | EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy |
| Q59334871 | Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines |
| Q90292724 | Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors |
| Q88013125 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers |
| Q97595643 | Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival |
| Q90241844 | Mutation profiling of cancer drivers in Brazilian colorectal cancer |
| Q92443760 | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
| Q96954604 | Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC) |
| Q64097897 | Prognostic impact of ATM mutations in patients with metastatic colorectal cancer |
| Q59337413 | Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer |
| Q57284277 | Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancer |
| Q92061487 | Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015 |
| Q88800645 | Right Versus Left Colon Cancer: Resectable and Metastatic Disease |
| Q64116155 | Significance of HER2 protein expression and gene amplification in colorectal adenocarcinomas |
| Q91739085 | Survival of patients with resected primary colorectal mucinous adenocarcinoma: A competing risk nomogram analysis |
| Q89975370 | The Effect of Cholecystectomy on the Risk of Colorectal Cancer in Patients with Gallbladder Stones |
| Q64061369 | The Role of M3 Muscarinic Receptor Ligand-Induced Kinase Signaling in Colon Cancer Progression |
| Q93088292 | The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer |
| Q89186319 | Trends in colorectal cancer incidence among younger adults-Disparities by age, sex, race, ethnicity, and subsite |
Search more.